ERIS Lifesciences Ltd (ERIS)
🎯 Key Takeaways
- ERIS Lifesciences is in a strategic transition phase, shifting focus from mature domestic formulations to high-growth segments like GLP-1, insulin analogs, and branded probiotics, while managing margin pressure from product mix changes. The company is actively pursuing market expansion in underpenetrated therapeutic areas and completing regulatory milestones, indicating a growth-oriented but near-term earnings-constrained trajectory.
- Revenue grew 15.4% QoQ to ₹873 in Q1FY27.
- ⚠️ 1) Margin pressure persists due to product mix shift toward lower-margin therapies in GLP-1 and insulin segments, which may sustain near-term earnings
- Market Cap
- ₹17,128
- P/E Ratio
- 26.3
- P/B Ratio
- 4.39
- ROE
- 16.5%
- ROCE
- 13.6%
- Debt/Equity
- 0.59
- Div Yield
- 0.58%
- Promoter
- 54.1%
📖 The Story
ERIS Lifesciences is in a strategic transition phase, shifting focus from mature domestic formulations to high-growth segments like GLP-1, insulin analogs, and branded probiotics, while managing margin pressure from product mix changes. The company is actively pursuing market expansion in underpenetrated therapeutic areas and completing regulatory milestones, indicating a growth-oriented but near-term earnings-constrained trajectory.
📰 What's Happening
In Q1 FY27, ERIS reported 13% YoY revenue growth to ₹873 crore and 14.5% YoY PAT growth to ₹143 crore, driven by 14% organic growth in Domestic Branded Formulations and strong performance in GLP-1 and insulin segments. Despite this, EBITDA margin compressed to 34% from 35.8% due to a shift toward lower-margin therapies. Management highlighted progress on strategic priorities: targeting 70% of OAD market growth, commercializing Eris Bionxt, entering the ₹2,309 cr insulin analogs market, and completing CAPA actions for Swiss Parenterals by December 2026. The board also reappointed Sujesh Vasudevan as Independent Director and scheduled the AGM for September 25, 2026, to address governance matters.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 792 | 807 | 757 | 873 |
| Operating Profit | 219 | 211 | 204 | 224 |
| OPM % | 27.6% | 26.2% | 27.0% | 25.7% |
| Net Profit | 134 | 109 | 279 | 143 |
| EPS | ₹8.82 | ₹7.32 | ₹20.60 | ₹10.28 |
Revenue has shown sequential improvement, rising to ₹873 crore in June 2026 from ₹757 crore in March 2026, but net profit declined sharply to ₹143 crore from ₹279 crore in the prior quarter, reflecting margin compression and strategic investments. Operating profit margin dipped to 25.7% from 27% in the previous quarter, aligning with management's disclosure of product mix shifts toward lower-margin therapies. While revenue growth is accelerating, profitability remains volatile, with the June quarter's PAT at ₹143 crore significantly below the March quarter's ₹279 crore, suggesting near-term earnings normalization as the company executes its expansion strategy.
🔮 Management Outlook & What's Next
Management expressed confidence in capturing growth in high-potential segments, particularly GLP-1 and insulin analogs, and outlined specific targets including achieving 70% of OAD market growth, commercializing Eris Bionxt, and completing regulatory CAPA actions by December 2026. The company is prioritizing strategic expansion into underpenetrated therapeutic areas while deferring immediate profitability in favor of market share gains, indicating a deliberate shift in capital allocation toward long-term growth enablers.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 14 | 14 | 14 | 14 |
| Reserves | 2,841 | 2,758 | 3,889 | 3,078 |
| Borrowings | 2,478 | 2,735 | 2,310 | 2,389 |
| Total Liabilities | 7,036 | 7,022 | 7,366 | 7,160 |
| Fixed Assets | 662 | 513 | 5,188 | 676 |
| Investments | 67 | 79 | 62 | 68 |
| Total Assets | 7,036 | 7,022 | 7,366 | 7,160 |
The balance sheet shows stable leverage with D/E at 0.85 and consistent total assets of ₹7,366 crore as of March 2026, indicating disciplined capital management. Reserves have grown to ₹3,889 crore from ₹2,841 crore in March 2025, reflecting retained earnings and capitalization of strategic initiatives. Borrowings remain flat at ₹2,359 crore, suggesting no aggressive debt-funded expansion, while equity remains stable at ₹14 crore, implying minimal external dilution beyond routine ESOP issuances.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | +1,065 | +538 |
| Investing | -80 | -369 |
| Financing | -881 | -314 |
| Net Cash Flow | +104 | -145 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 54.9% | 54.9% | 53.9% | 54.1% |
| FII | 7.2% | 6.8% | 6.4% | 5.8% |
| DII | 19.4% | 20.3% | 20.4% | 20.7% |
| Public | 9.1% | 8.5% | 10.1% | 10.1% |
| # Shareholders | 59,438 | 54,713 | 51,656 | 50,798 |
FII holdings have increased from 5.75% in Q1FY27 to 6.39% in Q4FY26, while DII holdings rose to 20.72% from 20.35%, indicating institutional accumulation. Promoter holding has slightly declined to 54.14% from 54.85% over the last four quarters, but the trend remains stable. The growing number of shareholders (50,798 in Q1FY27) and consistent institutional interest suggest broadening market participation without significant promoter sell-off pressure.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Margin pressure persists due to product mix shift toward lower-margin therapies in GLP-1 and insulin segments, which may sustain near-term earnings volatility. 2) OAD segment growth targets depend on successful commercial execution and market penetration, which are execution risks. 3) The proposed amalgamation of ETL, AHL, and EOHPL requires regulatory and operational execution, with no guaranteed timeline or value creation outcome. 4) Despite revenue growth, profitability declined sharply quarter-on-quarter, indicating that top-line gains have not yet translated into sustainable earnings momentum.
📋 Recent Filings
- Announcement2026-09-28ERIS Lifesciences announced that its trading window will close on October 1, 2026, and remain shut until 48 hours after the unaudited quarterly result…
- 🟡 Board Meeting2026-09-25ERIS Lifesciences held its 20th AGM on 25 September 2026 via video conference, approving audited financial statements for FY2026, appointing a new dir…
- 🟡 Board Meeting2026-09-25ERIS Lifesciences held its 20th AGM on 25 September 2026 via video conference, approving the audited standalone and consolidated financial statements …
- 🔴 Corporate Action2026-09-22ERIS Lifesciences announced the allotment of 155,264 equity shares under its ESOP-2021 scheme on September 22, 2026, increasing paid-up capital from ₹…
- 🟡 Board Meeting2026-09-21ERIS Lifesciences announced the appointment of Akhil Awasthi as an additional non-executive independent director effective September 26, 2026, for a f…
- 🟡 Board Meeting2026-09-11ERIS Lifesciences announced the resignation of Executive Director and COO Krishnakumar Vaidyanathan effective September 30, 2026, to pursue external p…
- 🔴 Announcement2026-09-10ERIS Lifesciences clarified that a news article about a loan disclosure was inaccurate and urged investors to rely solely on official exchange filings…
- 🔴 Announcement2026-09-09ERIS Lifesciences announced it has secured a ₹45 crore term loan from Axis Bank, marking a routine financial adjustment that does not affect projected…
- 🔴 Announcement2026-09-07ERIS Lifesciences announced an analyst and institutional investor meeting scheduled for September 10, 2026, at 3:30 PM IST, conducted in person with B…
- 🔴 annual report2026-09-02ERIS Lifesciences Ltd reported FY26 revenue of ₹3,129 crore (8% YoY growth), EBITDA margin of 35.8% (73% YoY EBITDA growth), and PAT of ₹648 crore inc…
🧠 Analyst's Read
ERIS is executing a clear strategic pivot toward high-growth therapeutic segments, supported by strong segmental performance and targeted market entries, but near-term profitability is being sacrificed for market share gains. The key watchpoints are successful CAPA completion, execution of the OAD and insulin analog expansion plans, and whether margin recovery can materialize as scale and mix shift progress.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ERIS files new disclosures
Track ERIS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ERIS — FreeFree account · 2 AI queries/day